decades. A further, more rare modification of hydroxylated amino acids was revealed as O-linked mannose. This type of posttranslational modification was initially regarded as restricted to yeast cells and other fungi (6) . There it is introduced into a variety of proteins with essential functions for the yeast cells, like cell wall proteins, by action of a protein mannosyltransferase family residing in the endoplasmic reticulum (7) (8) (9) (10) (11) . According to current knowledge, O-mannosylation in mammalian cells is found in a limited number of proteins, among them glycoproteins of the brain, nerves, and skeletal muscle (12) (13) (14) . The only identified O-mannosylated protein is ␣-dystroglycan, an extracellular component of the dystrophin complex in membranes of skeletal muscle, nerves, and brain (15, 16) . Different from yeast cells, where O-mannose is elongated by neutral, linear oligomannose chains (7), the core mannose on human ␣-dystroglycan shows extensions with complex glycans terminating with sialic acid or fucose. As major component a tetrasaccharide with the structure NeuAc2-3Gal1-4GlcNAc1-2Man was characterized and claimed to represent the specific ligand for interaction with the laminin G domains (13, 17) . Structural variants of this tetrasaccharide were reported, including structures with Lewis (18) or HNK-1 (19) epitopes and a branched core mannose (20) .
Distinct forms of congenital muscle dystrophies (dystroglycanopathies) are caused by mutation defects of glycosyltransferases involved in O-mannosylation of ␣-dystroglycan (21, 22) . Among these the Walker-Warburg syndrome represents an autosomal recessive form of congenital muscle dystrophies that is characterized by severe brain malfunction and eye anomalies (23) . The subpopulation of Walker-Warburg syndrome patients suffers from a selective deficiency of glycosylated ␣-dystroglycan in skeletal muscle, which results from mutations in the POMT1/POMT2 genes and the concomitant loss of a functional O-mannosyltransferase (24, 25) .
Initiation of O-mannosylation is catalyzed by two homologues of the yeast protein mannosyltransferases, the POMT1 and POMT2, which are active only on co-expression and were shown to form a functional complex (26, 27) . In yeast the protein mannosyltransferases are not dependent on any target sequences as they catalyze in vitro even the O-mannosylation of pentameric peptides (28) . The mammalian homologues are not active in vitro on short peptides, but recombinantly in procaryote-expressed ␣-dystroglycan (26) . Accordingly, there is no information available on the structural requirements for the initiation of mammalian O-mannosylation (see also below). All other forms of glycosylation are controlled by structural features of the glycosylation target sites. In the case of N-glycosylation the consensus motif Asn-Xaa-Thr/Ser, which contains an asparagine residue as a potential target site, serves as a sequon in the co-translational modification of proteins (29) . Other glycosylation forms, like mucin-type O-glycosylation, are less specifically controlled by structural qualities of the substrate (30 -32) . About 20 polypeptide GalNAc-transferases with cell-specific expression patterns transfer the O-GalNAc modification sequon-independent into serine or threonine positions of proteins, but show some degree of selectivity with overlapping site preferences (33) . Also the acceptor site for O-GlcNAc does not display a definite consensus sequence. However, the fuzzy motif is marked by the close vicinity of proline residues, valines, and a downstream tract of serines, whereas other amino acids, like leucines and glutamines are disfavored (34) . O-Fucosylation again shows a sequon dependence by its restriction to the consensus sequence Cys-Xaa-Xaa-Gly-Gly-Ser/Thr-Cys within epidermal growth factor domains (4) .
A recent in vitro study has revealed evidence that mammalian O-mannosylation could be dependent on a consensus sequence (35) . However, based on this postulated sequon in human ␣-dystroglycan (hDG) 2 no other proteins could be identified in a BLAST search as potentially O-mannosylated.
Although initiation of glycosylation appears to be generally determined by structural properties of the substrate position, we revealed evidence in vivo for the existence of further control mechanisms involved in the initiation of mammalian O-mannosylation. We provide experimental support for the hypothesis that O-mannosylation is cis-controlled by upstream located peptide regions, which determine potential mucin-type O-glycosylation sites as O-Man targets in the endoplasmic reticulum. However, the substrate sites themselves also control the initiation of O-mannosylation by specific structural features. Identification of the structural requirements for O-mannosylation and the modified sites may enable the discovery of other proteins with potential O-mannosylation and hence reveal insight into the functional networks, in which this largely unexplored modification is involved.
EXPERIMENTAL PROCEDURES
Materials-All chemicals were purchased from Sigma and were of the grade "pro analysi." Exceptions are marked in the text. Proteins were handled at ϩ4°C, long time storage was at Ϫ20°C.
Cells and Cell Culture-Cell culture work was performed with media and plasticware from Biochrom (Berlin, Germany). Human embryonic kidney cell line EBNA-293 (Invitrogen) and mouse myoblast cell line C 2 F 3 (kindly provided by Dr. U. Hartmann, Institute of Biochemistry II, University of Cologne) were cultivated at 37°C and 7.5% CO 2 in Dulbecco's minimal essential medium, supplemented with 5 (EBNA) or 20% (C 2 F 3 ) fetal calf serum, 100 units/ml penicillin, and 100 g/ml streptomycin. Transfection was performed using the Superfect lipofection reagent (Qiagen, Hilden, Germany). Transfected cells were cultivated in the presence of 5 g/ml puromycin (Sigma). The supernatant was collected for purification of the recombinant proteins.
Generation of Glycosylation Probes-Glycosylation probes were amplified by PCR on a DNA Thermo-Cycler (Hybaid MBS, Thermo, Egelsbach, Germany) from EST clone 7309805 (Invitrogen). We used 1 ng of cDNA, 6.25 nM dNTPs (Peqlab, Erlangen, Germany), 25 pmol of sense and antisense primer, respectively (BioTeZ, Berlin, Germany), 1 unit of Taq Polymerase (Qiagen), and 2.5 l of Taq buffer in a volume of 25 l. The temperature program was: 5 min at 95°C, followed by 30 times for 20 s at 95°C, 20 s at 55°C, and 20 s at 68°C with a final extension of 5 min at 72°C.
To the probes hDG1-hDG11 the restriction sites NheI (5Ј) and BglII (3Ј) were added simultaneously with the indicated primer pairs listed in supplemental Table S1 . To the DNA of fusion proteins hDGdel1 and hDGdel2, containing two separate parts of dystroglycan, the restriction sites NheI (5Ј) and EcoRV (3Ј) were added to the N-terminal DNA part (A in supplemental Table 1 ) and EcoRV (5Ј) and BglII (3Ј) sites were added to the C-terminal part (B in supplemental Table S1 ).
Amplified cDNA was cloned in one step into a modified version of the eukaryotic expression vector pCEP-PU (pCEP4) via the restriction sites (5Ј 3 3Ј) NheI, EcoRV, and BamHI/BglII. The vector has an N-terminal BM40 secretion signal, a cytomegalovirus promotor, and a C-terminal strepII as well as a His 8 tag. For selection of transfected cells the vector contains an ampicillin and a puromycin resistance gene.
Enzymatic digestion of the amplified cDNA and the vector pCEP-PU with restriction endonucleases BamHI, BglII, EcoRV, and NheI (New England Biolabs, Frankfurt, Germany) was done according to the manufacturer's protocol. The DNA fragments were purified by agarose gel electrophoreses on a 1% agarose gel with 1 g/ml ethidium bromide (Invitrogen). The DNA was eluted from the gel with the QIAquick Gel Extraction Kit (Qiagen).
Ligation was performed with the T4 ligase (New England Biolabs) according to the manufacturer's protocol. The plasmids were transformed into Escherichia coli strain DH5␣ according to standard protocols. Transformed bacteria were selected overnight on LB-broth agar plates (Invitrogen) containing 200 mg/ml ampicillin at 37°C. Amplification occurred overnight in LB-broth liquid medium (Invitrogen) with ampicillin in a 37°C shaker. The DNA was purified by using a Plasmid Midi Kit (Qiagen).
The dystroglycan part of the hybrid fusion proteins was amplified by PCR (supplemental Table S1 ) with restriction sites NheI (5Ј) and EcoRV (3Ј) added simultaneously. The DNA of the tandem repeat domain of a MUC1 construct (36) was isolated with the restriction enzymes EcoRV (3Ј) and BamHI (5Ј). Both DNA fragments were cloned in one step into the vector pCEP-PU as described above. For the hybrid fusion protein MUC1-hDG the N-terminal domain of MUC1 was amplified and cloned N-terminal to a section of the dystroglycan mucin domain via restriction sites (5Ј 3 3Ј) NheI, EcoRV, and BamHI/BglII.
Isolation of Recombinant Proteins from Cell Culture Supernatant-The recombinant fusion proteins were purified from the cell culture supernatant by nickel-nitrilotriacetic acid affinity chromatography followed by reversed phase HPLC as described in Ref. 37 .
Isolation of the MUC1-VNTR Region of hDG-MUC1-3-The protein was digested with trypsin (Promega, Mannheim, Germany) in 0.1 M NH 4 HCO 3 for 16 h at 37°C. The tryptic peptides were separated by HPLC as described in Ref. 37 with a different gradient (8 -20% acetonitrile during 20 min, followed by 20 -28% acetonitrile during 1 min and 28 -48% during 20 min). Fractions were collected every minute. HPLC fractions containing the VNTR domain were identified by dot blot and detection with the anti-MUC1 tandem repeat-specific C595 antibody (37) . The absence of dystroglycan-derived peptides was proved by MALDI-MS on a REFLEX IV mass spectrometer (Bruker Daltonics, Bremen, Germany) with a nitrogen laser ( ϭ 337 nm) and with positive ion detection in the reflection mode. As matrix 2,5-dihydroxybenzoic acid (Bruker Daltonics) (40 mg/ml in acetonitrile, 0.1% trifluoroacetic acid, 2:1) was applied onto a stainless steel target. The spectra were analyzed with the Flex Analysis software.
Gel Electrophoresis and Western Blotting-SDS gels were either stained with silver or blotted onto nitrocellulose membranes (Protan BA 83, Schleicher & Schuell) in a semi-dry transfer cell (Trans-Blot SD, Bio-Rad). The fusion proteins were detected with anti-strepII mouse IgG (IBA, Göttingen, Germany) and peroxidase-conjugated rabbit anti-mouse IgG, (DAKO, Hamburg, Germany). Protein-antibody conjugates were detected by enhanced chemiluminescence (Roche Applied Science).
Monosaccharide Composition and Identification of the Core Sugar-Monosaccharide composition was determined by GC/MS of the trimethylsilylated 1-O-methylglycosides (38) on a Fison MD800 GC/MS (Thermo Fisher, Dreieich, Germany), equipped with a 15-m RTX5-SILMS column (Restek, Bad Homburg, Germany). After an isothermal phase at the initial temperature (100°C, 1 min), a gradient of 6°C/min up to 260°C was used. MS spectra were registered by electron impact ionization at 70 eV. Relative masses between m/z 100 and 700 were scanned every second at 400 V.
To identify the core sugar, the glycan chains were released from the protein by reductive ␤-elimination. For this purpose the glycoproteins were incubated with 0.5 M NaBH 4 in 50 mM NaOH for 18 h at 50°C. The reaction was stopped by adding 1 l of acetic acid. Salt was removed with 50 l of Dowex 50W-X8 (Bio-Rad) in a batch procedure. Excessive borate was codistilled as methylester in a stream of nitrogen by adding several 0.1-ml aliquots of 1% acetic acid in methanol.
Permethylation of Glycan Alditols-Permethylation of the glycan chains, released by reductive ␤-elimination, was done as described by Ciucanu and Kerek (39) .
Glycan Analysis by Collision-induced Dissociation-Electrospray (Q-TOF) Mass Spectrometry-Electrospray ionization
(ESI) mass spectrometric data were acquired in the positive ion mode on a QTOF2 (Waters, Dreieich, Germany) by static nanospray application of the methylated glycans according to Ref.
37.
Linkage Analysis of Glycans-Partially methylated alditol acetates were prepared from permethylated samples according to Ref. 37 and analyzed by GC/MS on a 15-m RTX5-SILMS column (Restek) with an initial temperature of 60°C. The gradient was from 60 to 100°C with 40°C/min followed by 10°C/ min up to 280°C. Masses were scanned between 100 and 450 Da.
Glycopeptide Analysis by Collision-induced Dissociation-(CID) Electrospray Mass Spectrometry-Prior to trypsin digestion (Promega, Mannheim, Germany) the glycoproteins were either partially deglycosylated by successive incubation with the exoglycosidases neuraminidase (Clostridium perfringens, New England Biolabs), ␤-galactosidase and ␤-N-acetylhexosaminidase (both Jack Bean, GLYKO, ProZyme, Nils, IL), or chemically desialylated in 0.1 M trifluoroacetic acid by heating for 1 h at 80°C. The exoglycosidases were removed by reverse phase HPLC on a C8 column (see "Purification of Recombinant Proteins") before trypsin digestion.
ESI-MS/MS analysis was performed on a PTMDiscovery System (HCT-Ultra, Bruker, Bremen, Germany) coupled with an online nano-LC system (Ultimate, LC-Packings, Dionex, Idstein, Germany) and a PepMap C18 column (75 m inner diameter, 5 cm). Ions were scanned with 8100 atomic mass units/s in a range of m/z 300 -2500 in MS mode and m/z 100 -3000 in MS/MS mode. MS/MS spectra were generated by CID (helium) fragmentation.
To search specifically for O-mannosylated glycan structures, in the first run the CID fragmentation pattern was generated to search for characteristic fragment ions or patterns. In a second run, MS/MS spectra of selected ions were generated by using preferred mass lists and time segments.
In Vitro Glycosylation Studies-In vitro glycosylation with O-GalNAc was performed according to Ref. 32 with slight modifications. We used 5 g of the synthetic peptide in 25 mM cacodylate buffer (pH 7.4) containing 10 mM MnCl 2 and 200 M UDP-GalNAc together with 2.5 l of the semipurified GalNActransferases rGalNAc-T1 and -T2 (32) . The mixture was incubated for 24 h at 37°C and stopped with 0.1% trifluoroacetic acid in water. (Glyco) Peptides were analyzed by MALDI-MS as described above.
RESULTS

Generation and Expression of Recombinant Glycosylation
Probes-In an attempt to localize the structural elements required for O-mannosylation we followed a recombinant approach that was based on glycosylation probes corresponding to sections of human ␣-dystroglycan (Fig. 1) . Ten recombinant hDG probes (truncation and deletion constructs) and three hybrid hDG-MUC1 probes were generated that comprised the entire hDG mucin domain (p418 -536, defined by clusters of Ser/Thr and a high Pro content) or truncated versions thereof and N-terminal sequence stretches p286 -417 of different lengths. The largest probe, hDG1, contained the entire mucin domain (p418 -536) and the N-terminal sequence p286 -417 (Fig. 1 ). All fusion proteins contained an N-terminal secretion signal peptide BM40/SPARC and C-terminal His 8 tags as well as strepII to facilitate their isolation from culture supernatants and their detection in Western blots. The probes were successfully expressed in the human kidney cell line EBNA-293 and isolated from culture supernatant. Three recombinant probes (hDG2 to hDG4) were expressed at very low levels and could not be included into the structural analyses. Two constructs were derived from hDG8 by deletion of peptide stretches ( Fig.  1 ): hDGdel1 lacks amino acids p392-417, and hDGdel2 lacks an extended strand-peptide upstream of the mucin domain (p368 -376).
The hybrid fusion proteins contained amino acids p286 -346 (hDG-MUC1-1), p286 -393 (hDG-MUC1-2), and p286 -418 (hDG-MUC1-3) of human ␣-dystroglycan fused to six tandem repeats of human MUC1, or the N-terminal sequence of human MUC1 (p23-100), fused to p393 to p504 of ␣-dystroglycan, corresponding to the probe hDG5 (MUC1-hDG) (Fig. 1) . All hybrid fusion proteins were cloned into the pCEP-PU vector and expressed as described above. As the dystroglycan part of hDG-MUC1-3 corresponds to hDG11 it was expected to be O-mannosylated. To analyze the MUC1 part separately, the protein was digested with trypsin and the VNTR-derived peptides were isolated by reverse phage HPLC.
Purification of the Proteins-The secreted proteins were purified from 1 liter of cell culture supernatant by immobilized nickel-affinity chromatography followed by reversed phase chromatography on a C8-silica column (Fig. 2) . Homogeneity and identity of the proteins was proven by silver staining of SDS gels and Western blot analyses with a monoclonal anti-strepII antibody (supplemental Fig. S1 ). No contaminating proteins were detectable and the silver-stained bands were demonstrated to be isographic with strep-tagged proteins. The glycosylation profiles of the probes were then analyzed by GC-MS and ESI-MS/MS with respect to sugar composition, the identity of the reducing sugar, and the sequence of the oligosaccharides (Fig. 2) .
Monosaccharide Analysis and Identification of the Core Sugar-The monosaccharide compositions were analyzed by GC/MS. To identify the sugars (mannose, Man; galactose, Gal; N-acetylglucosamine, GlcNAc; N-acetylgalactosamine, GalNAc; N-acetylneuraminic acid, NeuAc) selected ion traces of 
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FIGURE 1. Recombinant O-mannosylation probes expressed in EBNA-293 cells. All probes were cloned into the pCEP-PU vector containing the BM40 secretion signal and the His 8 and strepII tags. The numbers refer to the amino acid sequence of human ␣-dystroglycan. The largest probe, hDG1, contained the complete mucin domain of ␣-dystroglycan (p418 -536) and some additional N-terminal sequences. All other probes contained parts of hDG1: truncation probes (hDG5-11), deletion probes (hDGdel1, hDGdel2), and hybrid probes (hDG-MUC1-1, hDG-MUC1-2, hDG-MUC1-3, and MUC1-hDG). A, schematic presentation of probe design; B, amino acid sequences of truncation and deletion probes; C, amino acid sequences of hybrid probes. Analysis of the probes indicated the presence of two different types of glycans (Table 1) . Probes hDG5, hDG7, and hDG9 showed a monosaccharide composition consistent with the exclusive expression of mucin-type glycans (NeuAc, Gal, GalNAc, and GlcNAc) based on GalNAc as the core sugar. Glycans in probes hDG1, hDG6, hDG8, hDG10, and hDG11 were composed of the same monosaccharides, but additionally contained mannose. As core sugars in the latter probes we identified Man-ol beside GalNAc-ol, indicating the presence of two different glycosylation types on the same protein, i.e. glycans based on core Man and on core GalNAc (supplemental Fig. S2 and Table 1 ). In summary, probes containing N-terminal peptide region p286 -417 or sections thereof (p346 -417) were apparently O-mannosylated, whereas probes starting at amino acid p393 were exclusively modified with mucin-type O-glycans ( Table 1) .
The hybrid fusion proteins hDG-MUC1-1, hDG-MUC1-2, and MUC1-hDG were modified exclusively with mucin-type O-glycans. The same holds true for hDGdel1, whereas hDGdel2 and hDG-MUC1-3 were mannose positive (Table 1) . However, mannose on hDG-MUC1-3 was, however, restricted to the dystroglycan part of the hybrid fusion protein, because tryptic glycopeptides derived from the MUC1 tandem repeat domain were shown to be mannose negative (Table 1) .
Sorbitol was present as a contaminant in all chromatograms and should originate from chromatographic matrices. We tested a possible epimerization of glucose to mannose by adding glucose to a mannose-free glycoprotein standard and subjecting this mixture to the reductive ␤-elimination protocol followed by methanolysis. In the GC/MS chromatogram of this sample we could not detect any mannose or mannitol, indicating that the mannose detected in ␣-dystroglycan probes was not an artifact.
Oligosaccharide Analysis by ESI-MS/MS-
To analyze the oligosaccharide structures on hDG probes, the reductively eliminated glycans were converted to the methylated alditols and analyzed by static nanospray ESI-MS/MS (Fig. 3) . Additional signals at the relative masses m/z 1077 (M ϩ H), 1099 (M ϩ Na), 716 (M ϩ H), and 738 (M ϩ Na) were detected in ESI spectra of mannose-positive truncation probes (hDG1, hDG6, hDG8, hDG10, and hDG11) and the hybrid probe hDG-MUC1-3. The MS/MS spectra registered for these molecular ions indicated sequences consistent with NeuAc-Hex-HexNAc-Hex-ol (m/z 1077 and 1099) and Hex-HexNAc-Hex-ol (m/z 716 and 738) (Fig. 3) . In conjunction with the results from monosaccharide analysis these core Hex-based glycans presumably correspond to the O-mannose-based tetra-and trisaccharides (NeuAc-)Gal-GlcNAc-Man-ol, which are known to modify ␣-dystroglycan as minor glycan species (18) .
None of the MS1 signals indicating the presence of O-mannosylated glycans was detectable in the samples from the hybrid fusion proteins hDG-MUC1-1 and hDG-MUC1-2. The same holds true for the hybrid probe MUC1-hDG and the deletion probe hDGdel1. However, strong signals in the survey spectrum of deletion probe hDGdel2 indicated the presence of O-mannose glycans. This was confirmed by MS/MS indicating the presence of tri-and tetrasaccharide alditols with identical fragmentation patterns measured for molecular species derived from mannose-positive truncation probes (see above).
Linkage Analysis by GC/MS-To analyze the monosaccharide linkage pattern of the glycans, the permethylated glycans were hydrolyzed, reduced with NaBD 4 , and acetylated to generate the partially methylated alditol acetates. The partially methylated alditol acetates were then analyzed by GC/MS and identified via their retention times and characteristic fragmentation patterns (supplemental Fig. S3 ). Mannose-negative Glycans from mannose-positive probes showed the same partially methylated alditol acetate pattern with additional 2-substituted mannitol as indicated by characteristic fragment ions at m/z 133, 161, 177, 205 (145), and 249. In conjunction with sequence information and compositional data the linkage analysis confirmed that the major O-mannose-based oligosaccharides on human dystroglycan probes were identical with (NeuAc2-3)Gal1-4GlcNAc1-2Man-ol (supplemental Fig.  S3 ). However, we also detected permethylated mannitol in the GC/MS profiles of mannose-positive samples indicating the presence of unsubstituted core mannose.
Analysis of Glycopeptides-To localize the sites of O-mannosylation the fusion proteins were either partially deglycosylated by sequential exoglycosidase treatments (hDG1) or by desialylation (hDG6, hDG8) prior to trypsin digestion. The two independent experimental set-ups resulted in largely overlapping peptide and glycopeptide series covering major portions of the fusion proteins ( Table 2) . Digests of hDG1 yielded glycopeptides p374 -389, p390 -433, p462-470, p466 -470, and p471-475. Except for glycopeptide p390 -433 all other fragments of hDG1 were carrying two to three hexose and N-acetylhexosamine residues in equimolar proportions, a feature that is characteristic for mucin-type glycans. Only glycopeptide 
TABLE 2
Glycopeptide analyses of tryptic digests from hDG1, hDG6, and hDG8 by ESI (CID/ETD) tandem mass spectrometry p390 -433 exhibited a disproportionally high expression of hexose with ratios of Hex/HexNAc ranging from 1.3 to 3.0 (Table 2 ). This feature indicates the potential presence of mannose-based glycans on this glycopeptide. As a characteristic feature, the Thr/Ser cluster within the p390 -433 peptide is C-terminal flanked by a dipeptide of basic amino acids (TTTTKK).
A similar glycopeptide (p455-489) was found in the digest of hDG6 (Table 2 ). This fragment covered altogether 12 potential O-glycosylation sites, of which 6 are located within two Thr/Ser clusters (TTK and RTTTS). The Thr/Ser clusters and two single Thr residues are again flanked by basic amino acids. MS and MS/MS analyses revealed the presence of 7-10 hexoses and 2-9 hexosamines, a Hex/HexNAc ratio, which is only compatible with the assumption that a portion of the putative O-glycosylation sites is substituted with a single, non-elongated hexose.
The smallest tryptic glycopeptide fragment of hDG8 was identified as the 15-mer PATPSTDSTTTTTRR (Fig. 4) , which covered one of the two Ser/Thr clusters located within the mucin domain (Table 2 ). Among the various glycoforms of this peptide all species were characterized by a preponderance of hexose versus hexosamines. The glycopeptide registered at m/z 773.7 represents a glycoform composed of eight hexoses and only one hexosamine. Considering that only three potential O-glycosylation sites are located outside of the Ser/Thr cluster the majority of the hexoses must be linked to the sequence STTTTT, which is flanked by two Arg residues.
In Vitro Glycosylation Assays-The Ser/Thr clusters within the ␣-dystroglycan mucin domain are predicted to be substrates for mammalian UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (NetOGlyc 3.1). To test whether these sites are actually targets of the polypeptide GalNActransferases, we performed in vitro glycosylation studies based on 15-meric, partially overlapping peptides that covered the entire mucin domain (Table 3) . Surprisingly, most positions remained non-glycosylated or were substituted at low rates when using polypeptide GalNAc-transferases T1 and T2 either separately or in a mixture. Both enzymes catalyzed incorporation of only one to three GalNAc residues into the peptides, although up to 10 sites were predicted. This finding may indicate that putative substrate positions for O-mannosylation are presumably poor substrate sites for mucin-type O-glycosylation. Comparing the numbers of GalNAc residues transferred with the numbers predicted it appears that the Ser/Thr clusters, which are C-terminal flanked by two basic amino acids, are particularly poor substrates for enzymes initiating mucin-type O-glycosylation (refer to peptides 12 to 17, which contain 6 to 10 predicted sites).
DISCUSSION
Based on structural analyses of recombinant human ␣DG glycosylation probes (truncation, deletion, and hybrid fusion proteins) this study provides evidence for unique mechanisms involved in the control of mammalian O-mannosylation initia- tion in vivo. We demonstrate that sequence elements upstream of the target sites in the mucin domain are essential for activity of the POMT1-POMT2 complex, because recombinant constructs lacking these elements remain essentially free of O-linked mannose (Fig. 5) . The truncation probes hDG5, hDG7, and hDG9 were revealed as O-mannose-negative, but adding upstream sequences (p346 -392) as in hDG6, hDG8, hDG10, and hDG11 resulted in O-mannose-positive probes. The shortest upstream sequence that was necessary and sufficient for induction of O-mannosylation of the hDG mucin domain was peptide stretch p377-417 immediately adjacent to the mucin domain (Fig. 5) . The further specification of the activating peptide region came from two deletion probes demonstrating that the structural elements responsible for induction of O-mannosylation reside within a 41-meric peptide, a 15-mer (p377-391) and a 26-mer (p392-417), both of which are necessary, but not sufficient in the absence of the other. This activating peptide is located outside of the mucin domain, but adjacent to the highly O-mannosylated region within the domain that was identified in this study. The preferred target sites of the POMT1-POMT2 complex were localized within a region of the mucin domain that contains Ser/Thr clusters and single Thr residues that are flanked by one or two basic amino acids. Presumably, these characteristic structural elements within the highly O-mannosylated region of ␣DG are required for initiation, because a hybrid construct containing the activating ␣DG peptide (p377-417) and a truncated repeat domain of MUC1 was O-mannosylated only in the hDG part of the hybrid protein. This finding implies that initiation of O-mannosylation is actually controlled by two structural elements, one at or near the site where mannose is transferred to and another, which is upstream and more distant to the substrate site. This aspect distinguishes O-mannosylation from other glycosylation forms, where structural elements at or near the substrate site are exclusively determining whether the core sugar will be transferred or not. Attempts to transfer mannose residues from mannosyl dolicholphosphate in vitro onto 15-meric peptide substrates that corresponded to overlapping sequences of the hDG mucin domain were unsuccessful.
3 This is in agreement with previous results obtained with 10-meric peptides (26) . However, Manya et al. (35) later reported that 20-meric peptides of the hDG mucin domain can serve as substrates and that an 18-meric consensus sequence occurring 2-fold in the domain is preferentially O-mannosylated. The data of this in vitro study are in conflict with the results of the present study (Fig. 5) , because: 1) we could identify a series of other peptide regions of the mucin domain as O-mannosylated, and 2) O-mannosylation in vivo was strictly dependent on upstream regions, N-terminal of the mucin domain, containing hDG-specific structural elements. 3) Three fusion proteins that contained the proposed consensus sequence (hDG5, hDG7, and hDG9) were demonstrated to lack O-mannosylation. Hence, it is likely that the reported 18-meric consensus sequence does not provide the entire structural requirements essential for the effective initiation of O-mannosylation in vivo.
A conformational dependence of the POMT1-POMT2 complex activation is unlikely, because the entire region upstream of the mucin domain contains numerous proline residues. Using secondary structure prediction tools the relevant sequence stretch p377-417 is largely characterized by the random-coil structure (80%) and by an extended strand structure (mainly in p412-417).
The present in vivo study revealed evidence for the involvement of structural elements distant from the O-mannosylation substrate sites of the mucin domain. The structural features of peptide regions that flank the N-terminal hDG mucin domain were shown to be indispensable for the in vivo initiation of O-mannosylation (Fig. 5) . However, these features were not sufficient to induce transfer of core mannose to the tandem repeats of another mucin (MUC1) pointing to hDG-specific properties of the substrate sites. Attempts to replace the N-terminal hDG region that triggers O-mannosylation by a structurally unrelated peptide region from another mucin (N-terminal domain of MUC1) revealed that specific structural properties in the hDG peptide region upstream of the mucin domain and not the mere presence of flanking peptide regions are essential for O-mannosylation initiation.
Structural analysis of the glycans liberated from probes hDG1, hDG6, hDG8, hDG10, and hDG11 revealed the presence of both, mucin-type O-linked glycans and mannose-based glycans. The latter contained only a small fraction of oligosaccharides with complex extensions to tri-and tetrasaccharides, whereas the majority remained at the level of non-elongated 3 I. Breloy, T. Schwientek, and F.-G. Hanisch, unpublished data. core mannose. There is still controversy whether the binding of ␣-dystroglycan to laminin G domains is mediated by acidic mannose-based glycans (13, 41, 42) . Although we could verify the presence of potential mediators of laminin binding activity on a series of O-mannosylated probes, the hDG probes generated in the present study cannot be expected to bind to laminin-1. This assumption is based on an earlier report showing that an extended peptide region N-terminal of the mucin domain is essential for laminin binding (40) . However, some of the constructs generated in this earlier study, which lacked laminin binding activity, should carry O-mannose-based glycans according to the present study. This would mean that either the mannosylated glycans are not involved as ligands in the laminin binding of ␣-dystroglycan or that their mere presence is not sufficient to mediate interaction with the G domains. Lack of laminin-1 binding activity of the O-mannosylated hDG1 probe was confirmed by far Western blots. 4 
